XXII 22nd Century Group Inc.

22nd Century Group (Nasdaq: XXII) Supports Federal Proposal to Require Less Nicotine in All U.S. Cigarettes

22nd Century Group (Nasdaq: XXII) Supports Federal Proposal to Require Less Nicotine in All U.S. Cigarettes

  • FDA’s Proposed Rule Draws on Research That Supports Reduced Nicotine Content Cigarettes Are Less Addictive
  • 22nd Century Group’s FDA MRTP Authorized 95% Reduced Nicotine Cigarette Products Is Already Available to Meet Proposed Policy to Reduce Nicotine in All Cigarettes
  • VLN® Pilot Sales Across Circle K Stores in the Chicago Area Showing Strong Interest from Adult Smokers

BUFFALO, N.Y., June 22, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company dedicated to improving human health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, is now selling the first and only 95% reduced nicotine content cigarette compliant with the renewed federal policy initiative to require all cigarettes sold in the U.S. be made minimally or non-addictive.

“We are delighted by today’s announcement from the Biden Administration, which is great news for adults who smoke and for 22nd Century Group,” said John Miller, president of 22nd Century’s tobacco programs. “The FDA requiring tobacco companies to reduce the nicotine content in all cigarettes sold in the United States has long been seen as the most powerful tool in the fight to reduce smoking and its grave health effects on citizens.”

“We are excited to pilot sales of the first and only cigarette designed specifically not to create and sustain addiction, but to instead reduce the hold of cigarette addiction on adult smokers,” said Miller. “The facts clearly demonstrate that the overwhelming majority of smokers want to quit, but few are able to do so, even after repeated attempts with current smoking cessation therapies or alternative nicotine products. VLN® from 22nd Century offers a new approach in this fight – a tobacco cigarette that actually helps adult smokers reduce their nicotine consumption and smoke less. We are hopeful that many will also go on to quit their habit of smoking highly addictive cigarettes entirely.”

VLN® King and VLN® Menthol King 95% reduced nicotine content cigarettes from 22nd Century are the first and only cigarettes to secure the U.S. Food and Drug Administration’s Modified Risk Tobacco Product (MRTP) designation. Moreover, the FDA requires 22nd Century to also include “Helps You Smoke Less” on product packaging and advertising to further communicate to adult smokers the unique product attributes.

Both of 22nd Century Group’s reduced nicotine content products are being sold in a pilot program in the greater Chicagoland area through the nation’s second largest C-store chain, . Pilot sales have indicated that there is a strong interest in a cigarette to help smokers smoke less as they seek to take control of their smoking habit.

Upon completion of the pilot program, VLN® products are expected to advance to a national launch, making them available to more than 30 million adults who currently smoke highly addictive cigarettes in the U.S. Of those smokers, it is estimated that 70% want to quit. Each year, more than half of smokers make an attempt to quit, but the Centers for Disease Control and Prevention (CDC) data indicates only 7% succeed, regardless of the method they use. VLN® reduced nicotine content cigarettes provide an additional tool to help smokers break their habit.

The MRTP designation and associated claims granted to 22nd Century’s VLN® products were based on extensive, independent research showing that 22nd Century’s reduced nicotine content tobacco cigarettes smoke and taste like a conventional cigarettes, while containing 95% less nicotine. At that greatly reduced nicotine level, the clinical data and extensive federally-sponsored research show that 22nd Century’s products help smokers to smoke less, providing a new and innovative approach in the fight to reduce smoking in the U.S. Cigarette addiction continues to claim the lives of nearly half a million Americans each year.

About 22nd Century Group, Inc.

22nd Century Group, Inc. (Nasdaq: ) is a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science. With dozens of patents allowing it to control nicotine biosynthesis in the tobacco plant, the Company has developed proprietary reduced nicotine content (RNC) tobacco plants and cigarettes, which have become the cornerstone of the  to address the widespread death and disease caused by smoking. The Company received the first and only FDA MRTP authorization of a combustible cigarette in December 2021. In tobacco, hemp/cannabis, and hop plants, 22nd Century uses modern plant breeding technologies, including genetic engineering, gene-editing, and molecular breeding to deliver solutions for the life science and consumer products industries by creating new, proprietary plants with optimized alkaloid and flavonoid profiles, as well as improved yields and other valuable agronomic traits.

Learn more at , on , on , and on .

Cautionary Note Regarding Forward-Looking Statements

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking statements typically contain terms such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “explore,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in “Risk Factors” in the Company’s Annual Report on Form 10-K filed on March 11, 2021. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

Investor Relations & Media Contact:

Mei Kuo

22nd Century Group, Inc.

Director, Communications & Investor Relations

T: 716-300-1221

Darrow Associates Investor Relations

Matt Kreps

T: 214-597-8200

 



EN
22/06/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on 22nd Century Group Inc.

 PRESS RELEASE

22nd Century Group (Nasdaq: XXII) Reports Business Highlights and Fina...

22nd Century Group (Nasdaq: XXII) Reports Business Highlights and Financial Results for the Second Quarter 2022 Strong Chicago Pilot Exceeded Expectations, Accelerates VLN® Expansion in ColoradoAccretive GVB Biopharma Acquisition Doubles Corporate Revenue and Expands Market Leading Hemp/Cannabis CapabilitiesSecond Quarter Net Sales $14.5 Million, Up 73% from the Second Quarter 2021Strengthened Balance Sheet with $35 Million Above-Market Equity Offering to Support Accelerated VLN® Expansion BUFFALO, N.Y., Aug. 09, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: ), a leading agr...

 PRESS RELEASE

22nd Century Group (Nasdaq: XXII) to Announce Second Quarter 2022 Resu...

22nd Century Group (Nasdaq: XXII) to Announce Second Quarter 2022 Results on August 9, 2022 BUFFALO, N.Y., July 27, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: ), a leading agricultural biotechnology company dedicated to improving human health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, will host a live webcast on Tuesday, August 9, 2022, at 10:00 AM ET to discuss its 2022 second quarter results, which are to be reported in a press release at 6:00 AM ET the same day. During the webcast, James A. Mish, chief executive officer; John Mi...

 PRESS RELEASE

22nd Century Group (Nasdaq: XXII) Strengthens Balance Sheet to Acceler...

22nd Century Group (Nasdaq: XXII) Strengthens Balance Sheet to Accelerate the Expansion of VLN Launch Announces $35 Million Above Market FinancingBolsters Company’s Position with Ongoing Strategic Discussions BUFFALO, N.Y., July 21, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company dedicated to improving human health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, announced that it has entered into definitive agreements with several institutional investors for the purchase and sale of 17,073,...

 PRESS RELEASE

22nd Century Announces $35 Million Registered Direct Offering Priced A...

22nd Century Announces $35 Million Registered Direct Offering Priced Above Market under Nasdaq Rules BUFFALO, N.Y., July 21, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), leading agricultural biotechnology company dedicated to improving human health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of 17,073,175 shares of its common stock at a purchase price of $2.05 per share in a registered direct offering priced abov...

 PRESS RELEASE

22nd Century Group (Nasdaq: XXII) Supports Federal Proposal to Require...

22nd Century Group (Nasdaq: XXII) Supports Federal Proposal to Require Less Nicotine in All U.S. Cigarettes FDA’s Proposed Rule Draws on Research That Supports Reduced Nicotine Content Cigarettes Are Less Addictive22nd Century Group’s FDA MRTP Authorized 95% Reduced Nicotine Cigarette Products Is Already Available to Meet Proposed Policy to Reduce Nicotine in All CigarettesVLN® Pilot Sales Across Circle K Stores in the Chicago Area Showing Strong Interest from Adult Smokers BUFFALO, N.Y., June 22, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural bi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch